Lehi, Utah, November 2, 2023 -- CancerVax, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.
“I got into medicine to make a difference in people’s lives, said Dr. Cohen. “I realized that cancer patients needed more focus and more attention than other patient groups. I feel grateful that I have been exposed to many opportunities to help both patients and care givers as an oncology physician.”
“Dr. Cohen is a lovely man with incredible experience and noble intentions,” said CancerVax CEO, Ryan Davies. “His dedication to the field of oncology is inspiring.”
Dr. Ezra Cohen is the Chief Medical Officer of Oncology for Tempus Labs in Chicago, a company dedicated to improving patient outcomes in oncology and other medical indications. Prior to joining Tempus Labs, Dr. Cohen was a Professor of Medicine, Division Chief Hemotology/Oncology and Associate Director of Moores Cancer Center at the University of California at San Diego. Before that Dr. Cohen was an Associate Professor at University of Chicago. He received his Doctor of Medicine at the University of Toronto.
This Podcast can be viewed at https://cancervax.com/videos/ceo-podcast/ezra-cohen-tempus-labs.
For more information about CancerVax, please visit http://www.cancervax.com/.
CancerVax, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we are developing a pipeline that includes three innovative projects: (1) treating Ewing sarcoma, a deadly children’s cancer, (2) a Universal Cancer Vaccine that will detect, mark, and destroy only cancer cells while leaving healthy cells in-tact, and (3) a low cost Universal CAR-T Cell Platform that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells. All of our immunotherapy technologies are designed to be delivered as injections. We look forward to the day when treating cancer will be as simple as getting a flu shot – a better way to treat cancer.
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.
Press Contact:
CancerVax, Inc.
Tel: (805) 356-1810
communications@cancervax.com